Gilead talks access in India as sofosbuvir patent opposer flaws its licensing approach
This article was originally published in Scrip
Executive Summary
Gilead Sciences is working on an "appropriate" access and pricing approach in resource-limited countries like India for its hepatitis C treatment, sofosbuvir, currently the subject of a pre-grant patent opposition by the US based non-profit group, Initiative for Medicines, Access and Knowledge (I-MAK).